Date receipt dossier
EudraCT number
2017-004971-30
Company / Sponsor
FluGen Inc.
Phase
IIa
Treated organism
Humans
Indication category
Vaccination
Disease
saesonal flu (H3N2)
Therapeutic approach
Prevention
Genetic modification
recombinant H3N2 influenza virus: 6 intern genes of the replication defective A/Puerto Rico/8/34 (PR8) strain with hemagglutinine and neuraminidase from A/Brismane/10/2007 (H3N2) strain
Method of transfer of nucleic acid of interest
not applicable
Administered biological material
recombinant replication defective H3N2 influenza vaccin (BRIS10 M2SR)
Route of administration
Intranasal
Locations in Belgium
SGS, Antwerpen
Nr of subjects
24
Type of procedure
Contained use only
Current status
Authorized